PBAX | Phoenix Biotech Acquisition Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.91 - 5.95
52 Week Range	4.12 - 12.80
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	6,124
Average Volume	8,080
Shares Outstanding	6,234,580
Market Cap	36,472,293
Sector	Financial Services
Industry	Shell Companies
IPO Date	2021-11-30

Valuation
Profitability
Growth
Health
P/E Ratio	-16.71
Forward P/E Ratio	N/A
EPS	-0.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	0
Country	USA

Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. The company was incorporated in 2021 and is based in Oakland, California.

PBAX's peers: GLLI, SUNS, TGAA, MSSA, TETE

*Chart delayed

Analyzing fundamentals for PBAX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PBAX Fundamentals page.

Watching at PBAX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PBAX Technicals page.